Unitedhealth Group

UNH Healthcare & Pharma 3/10 Low Risk
3/10
Sector avg: 2.8/10

Unitedhealth Group has $79.4B in scheduled debt maturities. DebtCanary scores UNH at 3/10, suggesting manageable refinancing risk.

Maturity Schedule

Year 1 $6.1B Year 2 $3.5B Year 3 $3.6B Year 4 $3.7B Year 5 $3.9B Beyond 5 $58.7B
Period Amount Due % of Total
Year 1 (0-12 months) $6.1B 7.7%
Year 2 (12-24 months) $3.5B 4.4%
Year 3 (24-36 months) $3.6B 4.5%
Year 4 (36-48 months) $3.7B 4.6%
Year 5 (48-60 months) $3.9B 4.9%
Beyond 5 Years $58.7B 73.9%
Total Scheduled Maturities $79.4B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$6.1B
Interest Coverage
4.7x
Debt/Equity
N/A
Cash Coverage
4.01x
Operating Income
$19.0B

Score Components

Component Value Weight
Near-Term Maturity Concentration 7.7% 30%
Interest Coverage Ratio 4.7x 25%
Debt-to-Equity Ratio N/A 25%
Cash Coverage of Near-Term Debt 4.01x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-03-02. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Unitedhealth Group →